"O" - Chester Clinic:

Proteomics: an evolving technology in laboratory medicine

Internet Journal of Medical Update 2010 January;5(1):35-41 Internet Journal of Medical Update Journal home page: http://www.akspublication.com/ijmu Review Article Proteomics: an evolving technology in Laboratory Medicine Dr. Javed Akhter*Ψ PhD, Dr. Waleed Al Tamimi* PhD, Dr. Abubaker El Fatih* FRCPath and Dr. D J Venter† MD


Preventing Drug Overdoses in Oklahoma Drug overdose deaths in Oklahoma have risen sharply during the past decade, according to Oklahoma City Addiction Medicine physicians Hal Vorse, MD, and Billy Stout, MD. Between 2002 and 2010, the Oklahoma Bureau of Narcotics and Dangerous Drugs Control (OBN) reports the number of overdose deaths in the state rose from 470 to 814 per year. Preliminary data indicates there were at least 795 drug overdose deaths in Oklahoma in 2011. Seventy-seven percent of the deaths were due to the use of prescription drugs in combination with other prescription drugs or alcohol.


A Newsletter for the Employees of Orange County Public Schools November 2011 Volume 39 Number 3 A Super Surprise at Andover Elementary Leann Freiburger, a second-grade express my thank you and gratitude for teacher at Andover Elementary, the commitment, dedication and support (pictured with Mr. Blocker and Principal he (her son) was given by his teacher,"

Osteo-1202 353.357

Osteoporos Int (2002) 13:353–357ß 2002 International Osteoporosis Foundation and National Osteoporosis Foundation Skeletal Status in Children, Adolescents and Young Adults with End-Stage Renal Failure Treated with Hemo- or Peritoneal Dialysis W. Pluskiewicz1, P. Adamczyk2, B. Drozdzowska3, K. Szprynger2, M. Szczepanska2, Z. Halaba4 andD. Karasek11Department and Clinic of Internal Diseases, Diabetology and Nephrology – Metabolic Bone Diseases Unit, 2Dialysis Division,Department of Pediatrics, Clinic of Nephrology, Endocrinology and Metabolic Disorders of Childhood, and 3Department andChair of Pathomorphology, Silesian School of Medicine in Katowice, Poland; and 4Outpatient Medical Care, Zabrze, Poland


TOP_August 2012_FINAL_v2_TOP 8/20/12 9:57 AM Page 1 CANCER CENTER PROFILE University of Arizona Cancer T-DM1 in Metastatic Breast The Expanding Role of the Oncology Pharmacist It's Just the Beginning for an Exciting New Class By Caroline Helwick The biggest newsmaker at the 2012 healthy tissue, T-DM1 not only has Annual Meeting of the American

Applicability of standard antibiotic toxicity tests to the ambient aquatic environment

F. L. Hellweger et al., Annals of Environmental Science / 2011, Vol 5, 61-66 APPLICABILITY OF STANDARD 1. INTRODUCTION ANTIBIOTIC TOXICITY TESTS Antibiotics, used extensively for human medicine and TO THE AMBIENT AQUATIC agriculture, enter the aquatic environment via ENVIRONMENT wastewater and other sources, where they have been found at measurable concentrations [1,2]. There may


J Oral Maxillofac Surg66:223-230, 2008 Outcomes of Placing Dental Implants in Patients Taking Oral Bisphosphonates: A Review of 115 Cases Bao-Thy Grant, DDS,* Christopher Amenedo, DDS,† Katherine Freeman, DrPH,‡ and Richard A. Kraut, DDS§ Purpose: In recent years, numerous cases of bisphosphonate-associated osteonecrosis of the jaw havebeen reported involving both intravenous and oral therapy regimens. The majority of these cases haveinvolved intravenous bisphosphonates. Subsequently, drug manufacturers and the US Food and DrugAdministration issued warnings about possible bisphosphonate-associated osteonecrosis of the jaw. TheAmerican Dental Association and the American Association of Oral and Maxillofacial Surgeons assembledexpert panels to formulate treatment guidelines. Both panels differentiated between patients receivingbisphosphonates intravenously and those receiving the drugs orally. However, the recommendationswere based on limited data, especially with regard to patients taking oral bisphosphonates. We wantedto ascertain the extent to which bisphosphonate-associated necrosis of the jaw has occurred in our dentalimplant patients. We also wanted to determine whether there was any indication that the bisphospho-nate therapy affected the overall success of the implants as defined by Albrektsson and Zarb.Patients and Methods: We identified 1,319 female patients over the age of 40 who had received dentalimplants at Montefiore Medical Center between January 1998 and December 2006. A survey about bisphos-phonate therapy was mailed to all 1,319 patients. Responses were received from 458 patients of whom 115reported that they had taken oral bisphosphonates. None had received intravenous bisphosphonates. All 115patients were contacted and informed about the risk of bisphosphonate-associated osteonecrosis of the jaw.Seventy-two patients returned to the clinic for follow-up clinical and radiological evaluation.Results: A total of 468 implants were placed in the 115 patients who reported that they had receivedoral bisphosphonate therapy. There is no evidence of bisphosphonate-associated osteonecrosis of thejaw in any of the patients evaluated in the clinic and those contacted by phone or e-mail reported nosymptoms. Of the 468 implants, all but 2 integrated fully and meet criteria for establishing implantsuccess. Implant success rates were comparable for patients receiving oral bisphosphonate therapy andthose not receiving oral bisphosphonate therapy.Conclusions: Guidelines for treatment of dental patients receiving intravenous bisphosphonate treatmentsshould be different than for patients taking the oral formulations of these medications. In this study, oralbisphosphonate therapy did not appear to significantly affect implant success. Implant surgery on patientsreceiving bisphosphonate therapy did not result in bisphosphonate-associated osteonecrosis of the jaw.Nevertheless, sufficient evidence exists to suggest that all patients undergoing implant placement should bequestioned about bisphosphonate therapy including the drug taken, the dosage, and length of treatment priorto surgery. For patients having a history of oral bisphosphonate treatment exceeding 3 years and those havingconcomitant treatment with prednisone, additional testing and alternate treatment options should be con-sidered.© 2008 American Association of Oral and Maxillofacial SurgeonsJ Oral Maxillofac Surg 66:223-230, 2008

Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort

ARTHRITIS & RHEUMATISM Vol. 60, No. 5, May 2009, pp 1496–1507 DOI 10.1002/art.24469 © 2009, American College of Rheumatology Premature Atherosclerosis in Pediatric Systemic Lupus Erythematosus Risk Factors for Increased Carotid Intima-Media Thickness in the Atherosclerosis Prevention in Pediatric Lupus Erythematosus Cohort Laura E. Schanberg,1 Christy Sandborg,2 Huiman X. Barnhart,1 Stacy P. Ardoin,1 Eric Yow,1


Home Loan Application - Building LoanPlease complete the following form and fax it to our Customer Contact Centre on (011) 632 2359 or email it to [email protected] A. – Application details Close Corporation o Further Home Loan o Convert from Home Loan to One Account o Home Loan account number B. – Personal details


Los Teques MeTro venezuela invests in rePAr: buiLding 8 refinery uniTs AT once brAskeM rAises funds wiTh MegA deAL ciTy of sALvAdor geTs second MArine ouTfALL [ TEO ] Odebrecht Entrepreneurial Technology"Everything we have built will only maintain its value if,


Vi ringraziamo per aver acquistato una fotocamera digitale Olympus. Prima di iniziare ad usare la vostra fotocamera, leggete attentamente queste istruzioni per ottenere i migliori risultati e per una maggior durata della macchina. Conservate il manuale in un posto sicuro per futuro riferimento. Prima di fare fotografi e importanti, vi consigliamo di scattare alcune fotografi e di prova, per acquisire


Obra Social del Personal de la Industria Ladrillera a Máquina OBRA SOCIAL DEL PERSONAL DE LA INDUSTRIA LADRILLERA A MAQUINA O. S. P. I. L. M. Presentamos a todos los beneficiarios de O.S.P.I.L.M. la Cartil a Prestacional Edición 2014. La Obra Social del Personal de la Industria Ladril era a Máquina, brinda todas las prestaciones incluidas en el P.M.Ovigente con las modificaciones que puedan establecerse. Este hecho surge como resultado de haber analizado el


Water Dispersible Granular Biofungicide Active Ingredient: Net Weight: 5 Pounds Bacillus amyloliquefaciens strain D747* . . . . . . . . . . . . . 25.0% EPA Reg. No. 70051-108 EPA Est. No. 70051-CA-001 *Contains a minimum of 5×1010 colony-forming units (cfu) per gram Certis USA, L.L.C. KEEP OUT OF REACH OF CHILDREN


Physician Guidelines About These GuidelinesAs an initial step in developing this document, the Orange County Vital Aging (OCVA) team reviewed published guidelines for managing D i s C l A i m e r dementia from the American Geriatrics Society, the American Academy of Family Physicians, and the College of Physicians. This provided a solid

Microsoft word - 27_349_branzila_14.doc

Environmental Engineering and Management Journal September 2014, Vol.13, No. 9, 2337-2342 "Gheorghe Asachi" Technical University of Iasi, Romania DECONTAMINATION OF SYNTHETIC WASTEWATER CONTAINING PHARMACEUTICAL CONTAMINANTS BY ANODIC OXIDATION WITH BORON- DOPED DIAMNOND (BDD) ELECTRODE


Social Status Predicts How Sex Steroid ReceptorsRegulate Complex Behavior across Levels ofBiological Organization Lauren A. O'Connell and Hans A. Hofmann Institutes for Cellular and Molecular Biology (L.A.O., H.A.H.) and Neuroscience (H.A.H.) and Section ofIntegrative Biology (L.A.O., H.A.H.), The University of Texas at Austin, Austin, Texas 78712


Implementation of Bio Suisse Standards for producers outside of Switzerland ImplementatIon of BIo SuISSe StandardS decISIonS of the BIo SuISSe laBel Edition of 16 February 2009 Implementation of Bio Suisse Standards for producers outside of Switzerland Implementation of Bio Suisse Standards for producers outside of Switzerland foreword This compilation of regulations on the implementation of Bio Suisse Stand-


Distributed in Australia by Orthotic & Prosthetic Centre Pty Ltd, Trading as OPC Health 151-159 Turner Street PORT MELBOURNE VIC 3207 T: 03 9681 9666 F: 03 9681 9366E: [email protected] OPC HEALTH ABN: 26 454 494 673 ACN: 005 863 525 SECTION 1 – Chemical Product and Company Identification

Anti-inflammatory effect of antioxidant pequi (caryocar brasiliense) oil capsules and antioxidant effect of vitamin d and physical activity on systemic lupus erythematosus patients

Montalvão et al. J Rheum Dis Treat 2016, 2:029 Journal of Rheumatic Diseases and Treatment Case Series: Open Access Anti-inflammatory Effect of Antioxidant Pequi (Caryocar Brasiliense) Oil Capsules and Antioxidant Effect of Vitamin D and Physical Activity on Systemic Lupus Erythematosus PatientsThaís Muniz Montalvão1,2, Ana Luisa Miranda-Vilela2,3*, Cesar Koppe Grisolia2 and Leopol-

Les rendez-vous de la santé - orléans

à 20 H 30 au Muséum Mercredi 4 avril 2007 Sexualité et vieillissement au masculin : au-delà de cette limite votre ticket est toujours valable ? Conférence/débat avec : Dr Dominique DELAVIERRE, médecin urologue et andrologue au CHRO, président sortant de la Société d'Andrologie de Langue Française,


Hélène Delerue Niagara Falls, Ontario Université du Québec à Montréal McGill University PRATIQUES DE PROTECTION DES ACTIFS INTELLECTUELS: UN ÉTAT DE L'ART Comment les entreprises protègent-elles leurs actifs intangibles et leur propriété intellectuelle ? Comment les entreprises s'approprient-elles la valeur de leurs investissements en R&D ? En d'autres termes, comment maintiennent-elles l'unicité et la valeur de la propriété intellectuelle? Ce papier présente une revue de la littérature et fait état des différentes pratiques susceptibles de compléter et renforcer les mécanismes légaux de protection des actifs intellectuels.